Tom Winnifrith Bearcast: is Big Sofa fecked and why - after 4 years of losses - Virgin really should be
Bluebird Merchant Ventures stance upgrade– an “Agreement” supporting our positive view of the gold production opportunity…
I may have mentioned a few times that I thought Neil Woodford had lost his marbles when he went pretty much all-in on early-ish stage biotech stocks in recent years but although everyone will be aware of the high profile disasters such as Northwest Biotherapeutics and Circassia (CIR), I thought that I would highlight a couple more examples this weekend that hit my radar this week showing how difficult / impossible it can be to pick biotech winners. First up, the business formerly known as Oxford Pharmascience, now Abaco Capital (ABA).
Search ShareProphets |
Recent Comments |